Study of A3309 in Patients With Dyslipidemia

A Phase IIa, Double-blind, Randomised, Placebo-controlled, Dose-finding Efficacy and Safety Study of A3309 in Patients With Dyslipidemia

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01069783

Enrollment

Registered

2010-02-17

Start date

2010-02-28

Completion date

2010-09-30

Last updated

2024-03-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dyslipidemia

Keywords

dyslipidemia, cholesterol, LDL

Brief summary

The purpose of this trial is to determine the efficacy and safety of A3309 administered to patients with dyslipidemia (high cholesterol levels).

Interventions

DRUGA3309

A3309 in two different dosage levels

DRUGPlacebo

Placebo comparator once daily for the duration of the trial

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Patients meet protocol specified criteria for dyslipidemia and has successfully completed study requirements with no clinically relevant findings

Exclusion criteria

* Medical history or medical condition that would not make the patient a good candidate for the study or would limit the patient´s capability to complete the study

Design outcomes

Primary

Measure	Time frame
Change from baseline in low-density lipoprotein (LDL) cholesterol	eight weeks

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 4, 2026